Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (7,654,575)	$ (3,797,198)
Adjustment to reconcile net loss to net cash used in operating activities:
Stock based compensation	1,030,415	425,844
Depreciation and amortization	1,495
Changes in operating assets and liabilities:
Prepaid assets	534,612	222,730
Accounts payable	521,114	796,208
Deferred revenue	(24,315)
Net cash used in operating activities	(5,591,254)	(2,352,416)
Cash flows from investing activities:
Purchases of property and equipment	(476,128)
Net cash used in investing activities	(476,128)
Cash flows from financing activities:
Net proceeds from issuance of common stock	28,023,564
Proceeds from issuance of common stock for stock option exercises	655,253
Proceeds from issuance of common stock for warrant exercises	180,212
Net cash provided by financing activities	28,859,029
Effect of exchange rate changes on cash and cash equivalents	(37,330)	(11,510)
Net change in cash and cash equivalents	22,754,317	(2,363,926)
Cash and cash equivalents at beginning of period	35,300,805	28,094,936
Cash and cash equivalents at end of period	58,055,122	25,731,010
Supplemental disclosure of non-cash investing and financing activities:
Issuance of common stock for accrued research and development expense		1,132,013
Cashless exercise of warrants	$ 416